Unknown

Dataset Information

0

Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate.

ABSTRACT: 10-Hydroxycamptothecin (HCPT) liposomes surface modified with stearyl glycyrrhetinate (SG) were prepared by the film dispersion method. Characterization of the liposomes, including drug release in vitro, pharmacokinetics and tissue distribution, was done. HCPT in plasma and tissues was determined by high-performance liquid chromatography (HPLC). Compared with the conventional HCPT-liposomes and commercially available hydroxycamptothecin injection (HCPT Inject), pharmacokinetic parameters indicated that SG-HCPT-liposomes had better bioavailability. Regarding tissue distribution, the concentration of HCPT loaded by SG modified liposomes in the liver was higher than other tissues and the risk to the kidney was lower than HCPT-liposomes and HCPT Inject. These results support the hypothesis that the HCPT-liposomes modified with SG show enhanced liver-targeting through the glycyrrhetinic acid (GA) receptor to be an efficient drug carrier, which may help to improve therapeutic methods for hepatic diseases in the future.

SUBMITTER: Zhou T 

PROVIDER: S-EPMC6610527 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Preparation and <i>in vitro</i> and <i>in vivo</i> evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate.

Zhou Ting T   Tang Xin X   Zhang Wei W   Feng Jianfang J   Wu Wei W  

Drug delivery 20191201 1

10-Hydroxycamptothecin (HCPT) liposomes surface modified with stearyl glycyrrhetinate (SG) were prepared by the film dispersion method. Characterization of the liposomes, including drug release <i>in vitro</i>, pharmacokinetics and tissue distribution, was done. HCPT in plasma and tissues was determined by high-performance liquid chromatography (HPLC). Compared with the conventional HCPT-liposomes and commercially available hydroxycamptothecin injection (HCPT Inject), pharmacokinetic parameters  ...[more]

Similar Datasets

Unknown Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy.
| S-EPMC6663921 | biostudies-literature
Unknown (S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity.
| S-EPMC6966462 | biostudies-literature
Unknown In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA.
| S-EPMC7438306 | biostudies-literature
Unknown Hyaluronic Acid Modified Hollow Prussian Blue Nanoparticles Loading 10-hydroxycamptothecin for Targeting Thermochemotherapy of Cancer.
| S-EPMC4679353 | biostudies-literature
Unknown Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.
| S-EPMC3335981 | biostudies-literature
Unknown Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization.
| S-EPMC3516839 | biostudies-other
Unknown Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects.
| S-EPMC6964270 | biostudies-literature
Unknown Preparation, Characterization, and Preliminary In Vitro Testing of Nanoceria-Loaded Liposomes.
| S-EPMC5618387 | biostudies-literature
Unknown Preparation, Characterization, and in Vitro/in Vivo Evaluation of Paclitaxel-Bound Albumin-Encapsulated Liposomes for the Treatment of Pancreatic Cancer.
| S-EPMC6649292 | biostudies-literature
Unknown Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
| S-EPMC6378220 | biostudies-literature